Stock Analysis

Teladoc Health First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

NYSE:TDOC
Source: Shutterstock

Teladoc Health (NYSE:TDOC) First Quarter 2024 Results

Key Financial Results

  • Revenue: US$646.1m (up 2.7% from 1Q 2023).
  • Net loss: US$81.9m (loss widened by 18% from 1Q 2023).
  • US$0.49 loss per share (further deteriorated from US$0.42 loss in 1Q 2023).
earnings-and-revenue-growth
NYSE:TDOC Earnings and Revenue Growth April 27th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Teladoc Health Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) missed analyst estimates by 3.9%.

Looking ahead, revenue is forecast to grow 3.3% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in the US.

Performance of the American Healthcare Services industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 2 warning signs for Teladoc Health that you need to be mindful of.

Valuation is complex, but we're helping make it simple.

Find out whether Teladoc Health is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.